<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240511061739N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-06-05</date_registration>
      <primary_sponsor>Pak Emirates Military Hospital</primary_sponsor>
      <public_title>Effect of dialysis fluid temperature in haemodialysis</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effects of different dialysate temperatures on adequacy of haemodialysis in patients with end stage renal disease</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-05-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/76863</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization would be done using computer generating sequencing. This would be done using online tools (calculator.net website). This would then be concealed in opaque envelopes, Blinding description: Patients and their caregivers would be blinded to the dialysate temperature, since this is set by the dialysis technicians and the patients are not aware of these settings. This parameter would not be visible on the display panel of the machines during the haemodialysis sessions, and would thus remain concealed from the patients
It would not be possible to blind the paramedical staff carrying out the dialysis sessions. However, they would have no role in data collection or analysis. Similarly, the principal investigator and two other doctors involved in data collection would not be blinded to the treatment groups. Since the outcome measures for this study are objective laboratory parameters, this lack of blinding is not expected to have a significant impact on the results.</study_design>
      <phase>N/A</phase>
      <hc_freetext>End-stage Renal Disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Dialysate Temperature 37.0 degree Celsius. Patients in this group would have the dialysate temperature set at 37.0 degree Celsius when the machine is being setup for a dialysis session. The same temperature of dialysate would be maintained throughout the session of 4 hours duration. Ultrafiltration would be done to the usual dry weight. Intervention 2: Intervention group 2: Dialysate Temperature 36.0 degree Celsius. Patients in this group would have the dialysate temperature set at 36.0 degree Celsius when the machine is being setup for a dialysis session. The same temperature of dialysate would be maintained throughout the session of 4 hours duration. Ultrafiltration would be done to the usual dry weight.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:


When:


To whom:


Conditions:


Where to obtain:


How to obtain:


Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Altaf Hussain</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>The Mall Road</address>
        <city>Rawalpindi</city>
        <country1>Pakistan</country1>
        <zip>4600</zip>
        <telephone>+92 302 5757487</telephone>
        <email>altafhussainafridi8@gmail.com</email>
        <affiliation>Pak Emirates Military Hospital</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Altaf Hussain</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>The Mall Road</address>
        <city>Rawalpindi</city>
        <country1>Pakistan</country1>
        <zip>46000</zip>
        <telephone>+92 302 5757487</telephone>
        <email>altafhussainafridi8@gmail.com</email>
        <affiliation>Pak Emirates Military Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients on maintenance haemodialysis for at least 3 months
Use of arteriovenous fistula for haemodialysis</inclusion_criteria>
      <agemin>19 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Acute kidney injury
History of intradialytic hypotension during last one month
Shortening of haemodialysis session for any reason
Interruption in haemodialysis session for more than 5 minutes
Patients known to have central venous stenosis
Uncooperative patients
Lack of consent</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N18.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>End stage renal disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Dialysate Temperature 37.0 degree Celsius. Patients in this group would have the dialysate temperature set at 37.0 degree Celsius when the machine is being setup for a dialysis session. The same temperature of dialysate would be maintained throughout the session of 4 hours duration. Ultrafiltration would be done to the usual dry weight.</i_keyword>
      <i_keyword>Intervention group 2: Dialysate Temperature 36.0 degree Celsius. Patients in this group would have the dialysate temperature set at 36.0 degree Celsius when the machine is being setup for a dialysis session. The same temperature of dialysate would be maintained throughout the session of 4 hours duration. Ultrafiltration would be done to the usual dry weight.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Urea reduction ratio. Timepoint: At the start and end of haemodialysis session. Method of measurement: Laboratory testing for serum urea levels.</prim_outcome>
      <prim_outcome>Online Kt/V. Timepoint: During the four hours haemodialysis session. Method of measurement: Online Clearance Monitoring module of Fresenius F4008 machines.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Pak Emirates Military Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-01-24</approval_date>
        <contact_name>Ethics Committee, Pak Emirates Military Hospital</contact_name>
        <contact_address>The Mall Road Rawalpindi Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
